Impact of payment source, referral site, and place of residence on outcomes after allogeneic transplantation in Mexico

Table 3 Characteristics and outcomes of 287 patients who underwent allogeneic hematopoietic cell transplantation according to healthcare coverage and payment method

Variable		OOP		Universal		Private		P value
		n = 139	100%	n = 73	100%	n = 75	100%
Sex	Male	81	58.3	41	56.2	46	61.3	0.81
	Female	58	41.7	32	43.8	29	38.7
Age	Median (years)	35	(15-80)	29	(16-65)	43	(15-67)	< 0.001
Diagnosis	AML	37	26.6	15	20.5	25	33.3	0.03
	ALL	39	28.1	25	34.2	12	16
	AA	20	14.4	10	13.7	6	8
	NHL	8	5.8	10	13.7	11	14.7
	MDN	10	7.2	4	5.5	11	14.7
	HL	9	6.5	4	5.5	4	5.3
	CML	7	5	3	4.1	0	0
	CMML	3	2.2	1	1.4	2	2.7
	PMF	3	2.2	0	0	1	1.3
	CLL	3	2.2	1	1.4	0	0
	MM	0	0	0	0	3	4
Residence	In state	46	33.1	41	56.2	36	48	0.003
	Out of state	93	66.1	32	43.8	39	52
Institution	Local	38	27.3	45	61.6	39	52
	Referral	101	72.7	28	38.4	36	48	< 0.001
Donor	Identical	51	36.7	29	39.7	31	41.3	0.78
	Haploidentical	88	63.3	44	60.3	44	58.7
Treatment lines	Median	2	(0-6)	2	(0-5)	1	(0-5)	0.62
DRI	Non-malignant	20	14.4	10	13.7	6	8	0.22
	Low	3	2.2	3	4.1	1	1.3
	Intermediate	56	40.3	36	49.3	25	33.3
	High	47	33.8	18	24.7	35	46.7
	Very high	13	9.4	6	8.2	8	10.7
HCT-CI	Median	0	(0-4)	0	(0-2)	1	(0-5)	0.08
Conditioning	MAC	57	41	51	69.8	35	46.7	0.001
	RIC	62	44.6	14	19.2	32	42.7
	NMA	20	14.4	8	11	8	10.7
CD34	Median	9	(1-16)	9	(2.4-19)	8	(1.8-23.7)	0.95
GVHD prophylaxis	PTCy	109	78.4	48	65.8	63	84	0.03
	CNI + MTX	30	21.6	25	34.2	12	16
Recovery	ANC	15	(10-24)	14	(10-22)	15	(10-48)	0.66
	Platelet	15	(10-100)	14.5	(10-24)	15	(10-44)	0.83
Graft failure		17	13.1	13	18.3	8	12.2	0.5
aGVHD	Grades 1-2	46	37.1	23	38.3	23	31.9	0.7
	Grades 3-4	14	11.3	8	13.3	6	8.3
cGVHD	Mild	14	14.9	11	19.6	15	23.8	0.09
	Moderate	13	13.8	13	23.2	13	20.6
	Severe	3	3.2	6	10.7	5	7.9
Early mortality	30 d	13	9.4	5	6.8	3	4	0.35
	60 d	24	17.3	7	9.6	6	8	0.12

DRI: Disease risk index; HCT-CI: Hematopoietic cell comorbidity index; GVHD: Graft versus host disease; AML: Acute myeloid leukemia; AA: Aplastic anemia; NHL: Non Hodgkin lymphoma; MDN: Myeldysplastic neoplasm; HL: Hodgkin lymphoma; CML: Chronic myeloid leukemia; CMML: Chronic myelomonocytic leukemia; MF: Myelofibrosis; CLL: Chronic lymphocytic leukemia; MM: Multiple myeloma; MAC: Myeloablative conditioning; CNI: Calcineurin inhibitor; MTX: Methotrexate; ANC: Absolute neutrophil recovery; PTCy: Post-transplant cyclophosphamide.